Pharmafile Logo
Pharmafocus logo
Advanced Search

immunotherapy

Showing 15 posts of 78 posts found.

BMS’ Opdivo scores eighth approval in Europe for bladder cancer

June 5, 2017
Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, Europe, European Commission, bladder cancer, immunotherapy

Bristol-Myers Squibb has announced that its flagship immunotherapy treatment Opdivo (nivolumab) has secured its eighth approval in Europe as the …

News

T cells found to ‘acquire knowledge’ to take fight to metastatic cancer

May 17, 2017
Research and Development Cancer, T cell, immunotherapy

T cells are widely known as being crucial in the fight against cancer within the body but little was known, …

News
800px-university_of_pittsburgh_tablet2

Immune system influences immunotherapy effectiveness, research shows

April 3, 2017
Research and Development, Sales and Marketing immunotherapy, nivolumab, opdivo

Preliminary research conducted at the University of Pittsburgh Cancer Institute (UPCI) has discovered a link between levels of certain immune …

News
shutterstock_141299494

Immunotherapy: The three major treatments that are changing cancer prognoses

March 13, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Cancer, MSD, Roche, immunotherapy, keytruda, oncology, opdivo, tecentriq

The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, …

Feature
800px-cocainehydrochloridepowder

Promising anti-cocaine treatment aims for human trials within a year

March 1, 2017
Research and Development University of Cincinnati, cocaine, immunotherapy

Researchers at the University of Cincinnati (UC) have developed a monocloncal antibody designed to treat cocaine addiction; its successful showing …

News
pharmafocus_march_cover

The March 2017 issue of Pharmafocus is now live!

February 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, FDA, Johnson & Johnson, MSD, Roche, Trump, crispr, immunotherapy, opdivo

The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing …

News

FDA clears Opdivo to treat most common form of bladder cancer

February 6, 2017
Sales and Marketing BMS, Bristol-Myers Squibb, MSD, bladder cancer, immunotherapy, keytruda, opdivo

Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …

News

New immunotherapy-based cancer research limits cancer spread by 75%

January 12, 2017
Medical Communications, Research and Development Cancer, cancer research, immunotherapy

Research conducted by the Sanger Institute in Cambridge has discovered 23 new genes associated with cancer cell’s spread through the …

News
merck_and_co

MSD looks to jump the gun with combination immunotherapy application

January 11, 2017
Research and Development, Sales and Marketing AstraZeneca, BMS, MSD, Roche, immunotherapy, keytruda

MSD, known as Merck in North America, has launched a bold move by filing Keytruda, and being accepted, for Priority …

News
amgen_hq

Amgen and Immatics enter $1bn immuno-oncology partnership

January 9, 2017
Research and Development, Sales and Marketing Amgen, immatics, immunotherapy

Amgen has announced it is to join forces with cancer immunotherapy biotech Immatics Biotechnologies in a partnership potentially worth over …

News
astrazeneca_logo_building

AstraZeneca’s head and neck cancer treatment clinical trials put on hold

October 31, 2016
Sales and Marketing AstraZeneca, clinical hold, clinical trials, immunotherapy, phase III

AstraZeneca, the Cambridge-based British company, had recruitment for its final stage Phase III trials placed on partial hold. The drug …

News

Roche’s immunotherapy cancer drug given FDA approval

October 19, 2016
Research and Development Cancer, FDA, Genentech, Roche, immunotherapy, lung cancer

Coming off the back of earlier positive news this month, Roche has revealed that their drug, Tecentriq, has been given …

News

Nice rejects BMS’ immunotherapy Opdivo for previously treated kidney cancer on pricing

July 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, QALY, immunotherapy, opdivo, regulation

UK regulators have rejected Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy Opdivo for previously treated kidney cancer on pricing and substantial uncertainty …

News
janssen_latest_logo_on_sign

Janssen says its immunotherapy daratumumab extends progression-free survival in combination study to treat multiple myeloma

June 10, 2016
Medical Communications, Research and Development Janssen, Phase III trials, drug trial, immunotherapy, multiple myeloma

Janssen said late-stage combination trials for its immunotherapy daratumumab increased progression-free survival for patients with multiple myeloma.  The company said …

News
rocheshanghai

FDA grants accelerated approval for Roche’s bladder cancer immunotherapy Tecentriq

May 19, 2016
Research and Development, Sales and Marketing FDA, Roche, atezolizumab, bladder cancer, immunotherapy, tecentriq

Roche (SIX: RO) has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Tecentriq (atezolizumab) …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025